GleamWall
中文EN

DFTX Definium Therapeutics, Inc.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1813814 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-100.8%
TTM EPS YoY-47.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-61.4%
ROA-51.5%
ROIC (approx.)-43.9%
Asset turnover—

Leverage & solvency

Liabilities / assets9.9%
Debt / equity0.04x
Current ratio15.53x
Interest coverage-51.91x

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-22.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$46.14M$48.66M$41.48M$33.52M$30.98M$29.81M$23.36M$21.76M
SG&A expense$26.14M$26.41M$17.74M$14.06M$14.69M$11.09M$8.80M$10.70M
Operating income-$72.28M-$75.08M-$59.22M-$47.58M-$45.67M-$40.90M-$32.16M-$32.46M
Interest expense$1.15M$1.23M$1.25M$1.27M$1.27M$2.34M$602,000$656,000
Net income-$50.96M-$158.99M-$77.10M-$50.44M-$67.27M-$42.74M-$23.35M-$34.74M
EPS (basic)-0.37-1.44-0.71—-0.78-0.50-0.27—
EPS (diluted)-0.46-1.44-0.71—-0.78-0.50-0.35—
Weighted avg. shares (diluted)137.35M110.68M108.79M—85.89M85.35M87.09M—
Balance sheet
Cash & equivalents$241.15M$655.27M$262.52M$257.84M$19.96M$33.39M$82.85M$273.74M
Short-term investments$805.70M$428.61M$110.90M$153.76M$189.11M$149.60M$129.59M$0
Current assets$1.05B$1.09B$380.56M$419.32M$215.85M$189.14M$221.70M$281.62M
Goodwill$19.92M$19.92M$19.92M$19.92M$19.92M$19.92M$19.92M$19.92M
Intangibles———————$0
Total assets$1.07B$1.11B$401.29M$440.10M$236.92M$265.09M$275.32M$302.15M
Current liabilities$67.73M$157.20M$81.11M$66.70M$65.42M$37.96M$30.48M$38.85M
Long-term debt$36.66M$36.47M$40.77M$40.58M$40.38M$41.19M$22.04M$21.85M
Total debt$36.66M$36.47M$40.77M$40.58M$40.38M$41.19M$22.04M$21.85M
Total liabilities$106.25M$194.22M$122.44M$107.77M$106.32M$79.69M$52.52M$60.70M
Shareholders' equity$968.03M$918.68M$278.85M$332.33M$130.60M$185.40M$222.81M$241.45M
Net debt-$204.49M-$618.80M-$221.75M-$217.26M$20.43M$7.80M-$60.82M-$251.89M
Shares outstanding136.89M134.37M104.04M98.78M76.77M75.80M75.51M75.10M
Cash flow statement
Operating cash flow-$52.98M-$52.78M-$42.63M-$42.98M-$29.57M-$29.60M-$29.42M-$25.35M
Investing cash flow-$372.80M-$316.74M$42.00M$34.98M$15.41M-$39.54M-$162.46M$0
Financing cash flow$11.66M$762.27M$5.31M$245.87M$749,000$19.65M$1.00M$3.81M
Stock-based compensation$10.78M$9.64M$7.13M$5.60M$5.82M$5.25M$3.43M$3.44M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.